Avalo Therapeutics plunges 29% as 2025 loss widens to $78.3M
Biotech's $50.1M R&D spend for Phase 2 LOTUS trial drives earnings miss ahead of Q2 2026 data catalyst
Avalo Therapeutics shares have tumbled 29% over the past three weeks as investors digest a widening net loss and the substantial cash burn required to advance its lead experimental treatment through a critical late-stage clinical trial.
The clinical-stage biotechnology company reported a 2025 net loss of $78.3 million, more than double the $35.1 million loss recorded in 2024. The shortfall was driven primarily by a $50.1 million investment in research and development—a $25.6 million increase year-over-year—funding the global Phase 2 LOTUS trial of abdakibart (AVTX-009) for patients with hidradenitis suppurativa, a painful chronic inflammatory skin condition.
The earnings performance significantly missed analyst expectations, with the company reporting an earnings per share loss of $5.84 compared to a consensus estimate of negative $1.61, representing a 263% shortfall. The stock closed at $13.42 on March 20, down 5.6% for the day and now trading below both its 50-day moving average of $15.81 and 200-day moving average of $12.85.
"2025 was a year of disciplined execution focused on the LOTUS trial," said Dr. Garry Neil, chief executive officer of Avalo. "We approach a transformational milestone with the topline data release expected in the second quarter of 2026."
The LOTUS trial, a randomized, double-blind, placebo-controlled study involving approximately 250 adults with moderate to severe hidradenitis suppurativa, completed enrollment in November 2025. The study evaluates the efficacy of subcutaneous bi-weekly and monthly dosing regimens over a 16-week treatment period, with the primary endpoint measuring the proportion of patients achieving a 75% reduction in abscess and inflammatory nodule count.
Despite the recent share price decline, analyst sentiment remains broadly positive. Analysts maintain a "Moderate Buy" rating on the stock with an average price target of $33 to $36—more than double the current trading price—a disconnect that highlights the binary nature of the upcoming data readout. According to analyst data, 11 analysts cover the stock, with 10 rating it a "buy" and 1 issuing a "strong buy" recommendation.
Avalo's financial position provides runway for the near term. The company reported cash, cash equivalents, and short-term investments of $98.3 million as of December 31, 2025, which management expects will fund operations into 2028. Net cash used in operating activities for 2025 totaled $51.5 million, indicating the company can sustain its current burn rate for approximately 1.9 years based on the current cash position.
General and administrative expenses also increased in 2025, rising to $22.9 million from $17.2 million in the prior year, primarily due to stock-based compensation and additional headcount to support the advancing clinical program.
The stock's recent underperformance reflects investor skepticism about the trial's chances of success. Avalo shares have fallen 22.5% over the past 10 trading days and now sit well below their 52-week high of $20.72 reached earlier in the year. The company's market capitalization stands at $248 million, with minimal revenue of $192,000 over the trailing twelve months.
Avalo Therapeutics, headquartered in Rockville, Maryland, focuses on developing treatments for rare and underserved conditions, particularly in immunological regulation. The LOTUS trial results will serve as a critical inflection point for the company, as positive data could validate the mechanism of abdakibart's high-affinity inhibition of IL-1β and support the drug's potential to address what management describes as a significant unmet medical need.
The Q2 2026 data release will determine whether analyst optimism is warranted or whether the market's current pricing reflects genuine concerns about the trial's prospects. For now, investors are bracing for what could be a volatile period as the binary catalyst approaches.